Changes in Hong Kong stocks | Yinnuo Pharmaceutical-B (02591) reversed the market and rose by more than 24% Recently, the company officially introduced the GLP-1 receptor agonist InnoLight® and was successfully insured

The Zhitong Finance App learned that Yinnuo Pharmaceutical-B (02591) reversed the market and rose by more than 24%, and fell more than 25% two days after entering the market. As of press release, it rose 23.38% to HK$39.44, with a turnover of HK$76.4949 million.

According to the news, recently, Yinnuo Pharmaceutical-B issued an announcement. According to separate announcements issued by the Shanghai Stock Exchange and Shenzhen Stock Exchange, the Company's H shares (H shares) were included in the list of eligible securities of Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect), which will take effect from December 8, 2025. The board of directors believes that being included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect will further expand the company's investor base and increase the trading circulation of H shares, thereby enhancing the investment value of H shares and the company's reputation in the capital market.

^{It is worth mentioning that according to Yinnuo Pharmaceutical's official WeChat, the company announced that the self-developed ultra-long-acting GLP-1 receptor agonist esupaglutide α (InnoLight®) will be officially included in the 2025 national medical insurance drug catalogue and will be implemented simultaneously with the new catalogue starting January 1, 2026, to provide more accessible high-quality innovative treatment options for type 2 diabetics in China. According to reports, esupaglutide α (InnoLight®) is a domestically produced ultra-long-lasting GLP-1 receptor agonist.} It has characteristics such as long half-life, low dosage frequency, and glucose-dependent regulation. It is the third ultra-long-lasting GLP-1 receptor agonist in the world and the first commercialized in Asia. It is also the first innovative drug of its kind, original in mainland China.